Comprehensive serum N‐glycan profiling identifies a biomarker panel for early diagnosis of non‐small‐cell lung cancer
PROTEOMICS · 2023-10 · 23 (20)
DOI: 10.1002/pmic.202300140 ↗Kurz gefasst
Fachartikel in der Zeitschrift PROTEOMICS, online erschienen am 20.07.2023. Verfasst von Yi Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Polysaccharides, Lung Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Aberrant serum N‐glycan profiles have been observed in multiple cancers including non‐small‐cell lung cancer (NSCLC), yet the potential of N‐glycans in the early diagnosis of NSCLC remains to be determined. In this study, serum N‐glycan profiles of 275 NSCLC patients and 309 healthy controls were characterized by MALDI‐TOF‐MS. The levels of serum N‐glycans and N‐glycosylation patterns were compared between NSCLC and control groups. In addition, a panel of N‐glycan biomarkers for NSCLC diagnosis was established and validated using machine learning algorithms. As a result, a total of 54 N‐glycan structures were identified in human serum. Compared with healthy controls, 29 serum N‐glycans were increased or decreased in NSCLC patients. N‐glycan abundance in different histological types or clinical stages of NSCLC presented differentiated changes. Furthermore, an optimal biomarker panel of eight N‐glycans was constructed based on logistic regression, with an AUC of 0.86 in the validation set. Notably, this model also showed a desirable capacity in distinguishing early‐stage patients from healthy controls (AUC = 0.88). In conclusion, our work highlights the abnormal N‐glycan profiles in NSCLC and provides supports potential application of N‐glycan biomarker panel in clinical NSCLC detection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- The Key Laboratory for Biomedical Photonics of MOE at Wuhan National Laboratory for Optoelectronics-Hubei Bioinformatics & Molecular Imaging Key Laboratory, Systems Biology Theme, Department of Biomedical Engineering, C…
ORCID-Profile: Yi Wang, Si Liu, Xin Liu, Liming Cheng
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, Y., Liu, S., Li, J., Yin, T., Liu, Y., Wang, Q., Liu, X., & Cheng, L. (2023). Comprehensive serum N‐glycan profiling identifies a biomarker panel for early diagnosis of non‐small‐cell lung cancer. PROTEOMICS, 23(20). https://doi.org/10.1002/pmic.202300140
Vancouver
Wang Y, Liu S, Li J, Yin T, Liu Y, Wang Q, et al. Comprehensive serum N‐glycan profiling identifies a biomarker panel for early diagnosis of non‐small‐cell lung cancer. PROTEOMICS. 2023;23(20). doi:10.1002/pmic.202300140
BibTeX
@article{Wang2023,
author = {Wang, Yi and Liu, Si and Li, Jiaoyuan and Yin, Tongxin and Liu, Yuanyuan and Wang, Qiankun and Liu, Xin and Cheng, Liming},
title = {Comprehensive serum N‐glycan profiling identifies a biomarker panel for early diagnosis of non‐small‐cell lung cancer},
journal = {PROTEOMICS},
year = {2023},
volume = {23},
number = {20},
doi = {10.1002/pmic.202300140}
}
EUVIMED